A new class of safer pain relievers
Official title: Arylepoxamides: A new class of potent, safer analgesics
Funded at Sparian Biosciences, INC. · NIH-10690777 · Data updated 2026-11-12
This study is testing a new type of pain relief medication called MP1000, which aims to help people manage pain without the risks of addiction that come with traditional opioids.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sparian Biosciences, INC. NIH-funded |
| Lab location | 1 site (New York City, United States) |
| Project start | December 15, 2018 |
| Project end | August 31, 2025 |
| Funding year | 2023 |
| Award (this year) | $4,506,061 |
| NIH project number | 5UH3DA048379-05 |
| Project ID | NIH-10690777 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals suffering from chronic pain who are currently using opioids or are seeking alternative pain relief methods.
✕Less likely to help
Patients who do not experience chronic pain or those who are not currently using opioids may not benefit from this research.
What this research studies
This research investigates a novel class of analgesics called arylepoxamides, which target a unique site in the brain to provide pain relief without the addictive side effects associated with traditional opioids. The approach aims to reduce opioid prescriptions and their associated risks by developing a compound, MP1000, that effectively alleviates pain from various sources while avoiding respiratory depression and dependence. The research includes preclinical studies and plans for a Phase 1 clinical trial to evaluate the safety and efficacy of this new pain medication.
Why it matters
Potential benefit: If successful, this research could lead to safer pain management options that reduce reliance on opioids and lower the risk of addiction.
How similar studies have gone: Other research has shown promise in developing non-opioid analgesics, but this specific approach with arylepoxamides is novel and untested in clinical settings.
Where this research is happening
-
Sparian Biosciences, INC.
New York City, United States Active
Researchers
- Principal investigator: Reich, Jeffrey — Sparian Biosciences, INC.
- Study coordinator: Reich, Jeffrey
Related research
Other NIH-funded projects on the same topics.
-
First-in-class, non-opioid pain medicine (SBS-147) for acute and chronic pain
A new non-opioid pill called SBS-147 may help adults manage acute and chronic pain with less risk of dependence or overdose.
-
SBS-226: a new medication that activates one opioid receptor and blocks another to treat opioid addiction
This project develops SBS-226, a potential medicine designed to reduce opioid cravings and withdrawal by activating the mu-opioid receptor while blocking the delta-opioid receptor for people with opioid use disorder.
-
Developing a new treatment for opioid use disorder
This study is testing a new medication called SBS-226 to help people with opioid use disorder by providing pain relief without the same risk of addiction that comes with regular opioids.
-
Creating new treatments for stimulant use disorder
This study is testing a new medication called SBS-518 that aims to help people struggling with stimulant use disorder, like those using methamphetamine or cocaine, by reducing their cravings without giving them a high, and there may be chances for patients to join early trials as the research moves forward.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.